R&D Scientists and algorithms: Finding the right balance in mode... The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
Market Access Navigating Europe's AI regulatory labyrinth: A strategic gui... For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Patients Approval is not access: Pilots’ real test is implementation A medicine can be nationally recommended and still be difficult to access if local systems are not ready to identify, offer, deliver, and monitor it.
News Pfizer, Valneva Lyme vaccine starts review in Europe After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.
News Manufacturing issues mar ITM's radiopharma filing, says FDA ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
Market Access Why global pharmaceutical reforms are quietly redirecting ra... Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.